Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.…
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
Whitehawk Therapeutics (NASDAQ: WHWK) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 37 employees.
The shares were at 3.070 USD on 20 November 2026, up 46.2% over 52 weeks. Its 52-week range is 1.970 USD to 5.495 USD: the price is 44.1% below the high and 55.8% above the low.
Its market capitalisation is 181.16M USD.
Whitehawk Therapeutics reports return on equity of -15.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 169.45M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 7.714 USD is 151.3% above the current price. The next earnings report is expected on 11 March 2027.